NCT02478515View on ClinicalTrials.gov

Evaluation of the Usefulness of a PRN Regimen Using Ranibizumab for Macular Edema Due to Branch Retinal Vein Occlusion

PHASE4CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

March 31, 2019

Study Completion Date

March 31, 2019

Conditions
Branch Retinal Vein Occlusion
Interventions
DRUG

Ranibizumab

Intraviteal injection of 0.5mg ranibizumab

Trial Locations (1)

467-8602

Nagoya City Univsersity, Nagoya

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Nagoya City University

OTHER